GlassScriptPhysician profile
Benedict C Wu
NPI 1730538596
$17,152.38
in general payments reported to CMS, 2019-2025
15 companies · $650 in 2025
The $650 reported for 2025 was less than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $2,517 · 2023: $12K · 2024: $2,328 · 2025: $650.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $9,000 · Food and Beverage: $3,082 · Honoraria: $1,548 · Travel and Lodging: $906 · Education: $99.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $9,000.00 |
| Food and Beverage | $3,081.76 |
| Honoraria | $1,548.00 |
| Travel and Lodging | $905.97 |
| Education | $99.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Argenx US, INC. | $10,137.93 | 2023-2024 | Vyvgart, Vyvgart Hytrulo |
| Boehringer Ingelheim Pharmaceuticals, INC. | $2,181.88 | 2022-2023 | |
| Blueprint Medicines Corporation | $1,548.00 | 2024 | Ayvakit |
| Incyte Corporation | $786.80 | 2023-2025 | Opzelura |
| Regeneron Healthcare Solutions, INC. | $639.26 | 2022-2024 | Dupixent |
| Janssen Biotech, INC. | $361.49 | 2022-2025 | Tremfya |
| Ucb, INC. | $341.79 | 2024-2025 | Bimzelx |
| Abbvie INC. | $315.24 | 2022-2024 | Rinvoq |
| Pfizer INC. | $278.78 | 2023-2025 | |
| Galderma Laboratories, L.P. | $166.69 | 2023-2025 | Nemluvio |
| Janssen Scientific Affairs, LLC | $145.57 | 2025 | Tremfya |
| Organogenesis INC. | $124.94 | 2022 | |
| Lilly USA, LLC | $54.18 | 2024 | Olumiant |
| Arcutis Biotherapeutics, INC. | $40.36 | 2025 | Zoryve |
| Aurinia Pharma U.S., INC. | $29.47 | 2023 | Lupkynis |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Benedict Wu listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.